Purdue Pharma Pleads Guilty Over Role in U.S. Opioid Epidemic
WEDNESDAY, Nov. 25, 2020 -- Purdue Pharma pleaded guilty to three criminal charges linked to the Oxycontin maker's role in the nation's opioid epidemic.
In a virtual hearing Tuesday with a federal judge in Newark, New Jersey, Purdue admitted that it paid doctors to write more prescriptions for the company's painkillers and paid an electronic medical records company to give doctors information on patients that encouraged the prescribing of opioids, the Associated Press reported.
Under a deal with the Justice Department, the company also admitted to providing misleading information to the U.S. Drug Enforcement Administration. The deal includes $8.3 billion in penalties and forfeitures, but Purdue would pay only $225 million to the federal government as long as it reaches a settlement with state and local governments and other agencies suing the company over the opioid crisis, the AP reported.
Purdue is owned by the Sackler family, who have agreed to pay $225 million to the federal government to settle civil claims. No family members face criminal charges, but their agreement does not prevent that from happening in the future, the AP reported.
© 2021 HealthDay. All rights reserved.
Posted: November 2020
Read this next
WEDNESDAY, Jan. 13, 2021 -- From 2010 to 2017, there were significant increases in the estimated rates of neonatal abstinence syndrome (NAS) and maternal opioid-related diagnoses...
WEDNESDAY, Dec. 30, 2020 -- Patients already receiving opioid use disorder (OUD) treatment continued to receive care during the early weeks of the COVID-19 pandemic, with some...
WEDNESDAY, Dec. 23, 2020 -- Walmart is being sued by the U.S. Justice Department for its alleged role in the nation's opioid crisis. A civil complaint filed Tuesday says Walmart...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.